Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00233909
Status:
COMPLETED
Last Update Posted:
2008-04-01
First Post:
2005-10-04
Brief Title:
A Trial of Gemtuzumab Ozogamicin GO in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia
Sponsor:
Kanisa Pharmaceuticals
Organization:
Kanisa Pharmaceuticals
Study Overview
Official Title:
An Open-Label Phase III Trial of Gemtuzumab Ozogamicin GO in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia
Status:
COMPLETED
Status Verified Date:
2008-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Chemotherapy drugs use different ways to stop cancer cells from dividing so they stop growing or die Zosuquidar may help Gemtuzumab Ozogamicin GO kill more cancer cells by making cancer cells more sensitive to the drug It is not known whether Gemtuzumab Ozogamicin GO is more effective with or without zosuquidar in treating acute myeloid leukemia
Detailed Description:
Purpose
Phase I Determine the optimal dose and schedule of GO and zosuquidar when used in combination
Phase II Determine the complete remission rate CRCRp
Phase I Determine the optimal dose and schedule of GO and zosuquidar when used in combination
Phase II Determine the complete remission rate CRCRp
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None